Quantbot Technologies LP Increases Stake in Alkermes plc $ALKS

Quantbot Technologies LP lifted its stake in shares of Alkermes plc (NASDAQ:ALKS) by 54.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,091 shares of the company’s stock after buying an additional 385 shares during the quarter. Quantbot Technologies LP’s holdings in Alkermes were worth $36,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of ALKS. JPMorgan Chase & Co. grew its holdings in Alkermes by 488.6% in the first quarter. JPMorgan Chase & Co. now owns 5,234,995 shares of the company’s stock worth $172,860,000 after purchasing an additional 4,345,523 shares during the period. Nuveen LLC purchased a new stake in Alkermes in the first quarter worth about $66,689,000. RTW Investments LP grew its holdings in Alkermes by 13.6% in the fourth quarter. RTW Investments LP now owns 7,557,835 shares of the company’s stock worth $217,363,000 after purchasing an additional 903,802 shares during the period. Nuveen Asset Management LLC grew its holdings in Alkermes by 109.5% in the fourth quarter. Nuveen Asset Management LLC now owns 1,659,821 shares of the company’s stock worth $47,736,000 after purchasing an additional 867,492 shares during the period. Finally, Stempoint Capital LP grew its holdings in Alkermes by 752.4% in the fourth quarter. Stempoint Capital LP now owns 416,968 shares of the company’s stock worth $11,992,000 after purchasing an additional 368,050 shares during the period. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Insider Transactions at Alkermes

In related news, SVP Christian Todd Nichols sold 3,334 shares of the firm’s stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $31.09, for a total value of $103,654.06. Following the sale, the senior vice president owned 86,208 shares in the company, valued at approximately $2,680,206.72. This trade represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.40% of the company’s stock.

Alkermes Stock Up 0.1%

Shares of NASDAQ ALKS opened at $28.97 on Friday. Alkermes plc has a twelve month low of $25.56 and a twelve month high of $36.45. The firm has a market cap of $4.78 billion, a P/E ratio of 13.93, a PEG ratio of 1.67 and a beta of 0.47. The company has a 50 day moving average of $28.31 and a 200 day moving average of $30.36.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.10. Alkermes had a net margin of 23.15% and a return on equity of 24.86%. The company had revenue of $390.66 million during the quarter, compared to analyst estimates of $343.20 million. During the same period in the previous year, the business earned $1.16 EPS. The firm’s revenue for the quarter was down 2.1% on a year-over-year basis. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS. As a group, equities analysts expect that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Royal Bank Of Canada upped their price objective on shares of Alkermes from $40.00 to $42.00 and gave the stock a “sector perform” rating in a report on Wednesday, July 30th. Wall Street Zen cut shares of Alkermes from a “strong-buy” rating to a “buy” rating in a report on Monday, May 5th. HC Wainwright restated a “neutral” rating and issued a $46.00 price objective on shares of Alkermes in a report on Monday, July 21st. The Goldman Sachs Group began coverage on shares of Alkermes in a report on Tuesday, July 15th. They issued a “buy” rating and a $43.00 price objective on the stock. Finally, UBS Group raised shares of Alkermes from a “neutral” rating to a “buy” rating and raised their price target for the company from $33.00 to $42.00 in a research report on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.08.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.